retatrutide mechanism triple agonist gip glp-1 glucagon receptor Phase 3: 28.7% Weight Loss (2026) The power of three: Retatrutide's

A recent University College London research estimates that 1.6 million adults in England, Wales and Scotland used GLP-1s, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025, to lose weight.

[16] Vials should be stored upright at 20-25 C in the original light-resistant container, protected from moisture and heat sources, and gently rolled between the palms to redissolve any oil stratification before withdrawal without vigorous shaking that can introduce air bubbles

Globally, GLP-1 therapies remain one of the fastest-growing drug classes

Tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, carries similar pregnancy warnings

Some users report increased libido

The study identified 1,799,261 patients with diabetes prescribed metformin, of which 1,083,492 (60.2%) had neither OSA diagnosis nor GLP-1 prescription